Jasper Therapeutics
JSPR
51 hedge funds and large institutions have $81M invested in Jasper Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 1 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 1
21% more funds holding
Funds holding: 42 → 51 (+9)
2% more capital invested
Capital invested by funds: $79.2M → $81M (+$1.78M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$4.04M |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$1.29M |
| 3 |
SCM
Saba Capital Management
New York
|
+$964K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$546K |
| 5 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$498K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.74M |
| 2 |
Goldman Sachs
New York
|
-$1.7M |
| 3 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$697K |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$617K |
| 5 |
MSU
Mizuho Securities USA
New York
|
-$457K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Walleye Capital
New York
| $862 | -$129K | -1,292 | -13% |
|
|
CS
52
Credit Suisse
Zurich,
Switzerland
| – | -$273K | -2,750 | Closed |
|
JSPR Hedge Fund Activity: Q4 2020 in Review
51 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2020, worth a combined $81M — up 2.2% from $79.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new JSPR positions and 1 closed out — a net gain of 10 holders — while 7 added to existing stakes and 15 trimmed.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $4.04M. The largest seller was Polar Asset Management Partners, cutting an estimated $2.74M.
- 51 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2020, up from 42 in Q3 2020.
- Funds reported $81M of Jasper Therapeutics stock for Q4 2020, up 2.2% quarter-over-quarter.
- 11 funds opened new Jasper Therapeutics positions in Q4 2020 and 1 closed out, a net change of +10 holders.
- The largest Jasper Therapeutics buyer in Q4 2020 was Mangrove Partners, an estimated $4.04M added.
- The largest Jasper Therapeutics seller in Q4 2020 was Polar Asset Management Partners, an estimated $2.74M sold.
Based on aggregated 13F filings for Q4 2020.